Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Amicus announced that the FDA accepted its NDA for migalastat to treat Fabry disease in patients with amenable mutations.
The FDA laid out eight observations it determined needed correction at the facility.
The June 30, 2017 lawsuit asserts that the EndoWrist violates seven Ethicon patents.
The company expected a submission date in late 2018.
Bexsero is the first vaccine in the world to receive the designation twice.
Joseph E. Payne was shown the door as CEO of Arcturus last week - a move that Payne is not taking lightly.
The company’s CEO confirmed the news yesterday.
The manufacturing error could cause the chamber to split and allow water into the patient’s breathing circuit.
AstraZeneca did not immediately respond to a request for comment.
Failing numbers are putting a strain on CEO Pascal Soriot’s pledge of achieving $45B of annual revenue by 2023.